374 related articles for article (PubMed ID: 15956887)
1. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.
Howell DL; Wasilewski K; Mazewski CM; Hudgins RJ; Meacham LR
J Pediatr Hematol Oncol; 2005 Jun; 27(6):326-9. PubMed ID: 15956887
[TBL] [Abstract][Full Text] [Related]
2. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
Iyer P; Molitch ME
Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816
[TBL] [Abstract][Full Text] [Related]
3. Dopamine receptor agonists for treating prolactinomas.
Colao A; di Sarno A; Pivonello R; di Somma C; Lombardi G
Expert Opin Investig Drugs; 2002 Jun; 11(6):787-800. PubMed ID: 12036422
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
5. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
7. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
Delgrange E; Maiter D; Donckier J
Eur J Endocrinol; 1996 Apr; 134(4):454-6. PubMed ID: 8640297
[TBL] [Abstract][Full Text] [Related]
8. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
9. Dopamine resistance of prolactinomas.
Molitch ME
Pituitary; 2003; 6(1):19-27. PubMed ID: 14674720
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of a large macroprolactinoma with cabergoline during pregnancy.
Liu C; Tyrrell JB
Pituitary; 2001 Aug; 4(3):179-85. PubMed ID: 12138991
[TBL] [Abstract][Full Text] [Related]
11. Combined cabergoline and recombinant human growth hormone treatment of an adolescent with a macroprolactinoma causing GH deficiency.
Cesario F; Borretta G; Meineri I; Muratori M; Pizzocaro A; Beck-Peccoz P
J Pediatr Endocrinol Metab; 1997; 10(2):231-6. PubMed ID: 9364359
[TBL] [Abstract][Full Text] [Related]
12. Cabergoline and quinagolide therapy for prolactinomas.
Webster J
Clin Endocrinol (Oxf); 2000 Nov; 53(5):549-50. PubMed ID: 11106914
[No Abstract] [Full Text] [Related]
13. Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.
Kawabata Y; Ueno Y; Horikawa F; Miyake H; Miki N; Ono M
Surg Neurol; 2008 Jan; 69(1):85-8; discussion 88. PubMed ID: 17967478
[TBL] [Abstract][Full Text] [Related]
14. Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With Prolactinoma.
Menon LP; Rahman W
J Investig Med High Impact Case Rep; 2021; 9():23247096211029750. PubMed ID: 34218714
[TBL] [Abstract][Full Text] [Related]
15. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
16. Late development of resistance to bromocriptine in a patient with macroprolactinoma.
Delgrange E; Crabbé J; Donckier J
Horm Res; 1998; 49(5):250-3. PubMed ID: 9568811
[TBL] [Abstract][Full Text] [Related]
17. Non-surgical management of cystic prolactinomas.
Bahuleyan B; Menon G; Nair S; Rao BR; Easwer HV; Krishna K
J Clin Neurosci; 2009 Nov; 16(11):1421-4. PubMed ID: 19699096
[TBL] [Abstract][Full Text] [Related]
18. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.
De Sousa SM; Chapman IM; Falhammar H; Torpy DJ
Endocrine; 2017 Feb; 55(2):618-624. PubMed ID: 27601019
[TBL] [Abstract][Full Text] [Related]
19. Beneficial Effects of High Doses of Cabergoline in the Treatment of Giant Prolactinoma Resistant to Dopamine Agonists: A Case Report with a 21-Year Follow-Up.
de Castro LF; Magalhães Gonzaga MF; Naves LA; Luiz Mendonça J; Oton de Lima B; Casulari LA
Horm Res Paediatr; 2018; 89(1):63-70. PubMed ID: 28954263
[TBL] [Abstract][Full Text] [Related]
20. Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review.
Behan LA; Draman MS; Moran C; King T; Crowley RK; O'Sullivan EP; Smith D; Thompson CJ; Agha A
Pituitary; 2011 Dec; 14(4):362-6. PubMed ID: 19191028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
